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E-mail address: elziber@yahoo.comGlucose ﬁltered by kidneys is reabsorbed into the proximal tubule through the sodium-coupled glucose
co-transporter (SGLT2). This promotes urinary excretion of glucose and results in lowering of plasma glu-
cose level. Administration of agents (e.g. dapagliﬂozin) that inhibits SGLT2 transporter have shown to be
associated with improvement in hyperglycaemia without clinically persistent electrolytes disturbances
or change in osmolarity. This may suggest that administration of dapagliﬂozin is effective and safe as
treatment for hyperglycaemia. Ongoing clinical trials will reveal the potential beneﬁt and safety of SGLT2
inhibitors as part of the therapy of type 2 diabetes.
 2010 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.1. Introduction
The kidneys reabsorb 99% of plasma glucose that ﬁlters through
tubules in normal individuals via mechanisms independent of
insulin. It is estimated that the ﬁlter load of glucose is 180 mg/
day, and only 500 mg of glucose is excreted in urine during the
day. In the majority of healthy individuals glucose is not detectable
in urine. When the capacity of glucose reabsorption has been ex-
ceeded, the surplus glucose is excreted in the urine, and this leads
to glucosuria. In normal individuals, the maximum transport rate
(Tm) for glucose in kidneys is reached at blood glucose concentra-
tion around 200 mg/Dl (11 mmol/L) [1]. Generally speaking, the
transport of glucose across cell membranes in different parts of
our body is achieved by the facilitative glucose transporters
(GLUTS) and sodium–glucose co-transporters (SGLTs – SGLT-1 in
the intestine and SGLT-2 in the kidney) [2]. Around 90% of glucose
reabsorption in the kidney is achieved by SGLT-2 which is located
in the brush border membrane of the ﬁrst segment of the proximal
tubule [2]. Thus, it is not surprising that the Tm of glucose in the
kidney is directly under the inﬂuence of SGLT-2. There was concern
about the safety of agents that inhibit SGLT-2 and this appeared
not to be relevant. Familial renal glucosuria is inherited defect in
SGLT-2 but individuals with this condition have normal renal func-
tion without other complications and is regarded as benign condi-
tion [3].ellitus. Published by Elsevier Ltd.
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O2. Sodium–glucose co-transporters (SGLT-2 inhibitors) and
diabetes
Recently, dapagliﬂozin (due to biochemical structure it can be
taken orally in unmodiﬁed form an advantage over other SGLT-2
inhibitors) has been shown to be a highly selective inhibitor for
SGLT-2. Dapagliﬂozin is a potent and selective inhibitor of SGLT-
2, with 1200-fold greater selectivity for SGLT-2 than SGLT-1 [3].
Administration of SGLT-2 inhibitors in normal and Zuker Diabetic
Fatty rats (ZDF) have been shown to be associated with a dose-
dependent increase in glucosuria and decrease in fasting and post-
prandial glucose and a glycated haemoglobin levels. Importantly,
the administration of SGLT-2 inhibitors was associated with signif-
icant improvements in insulin resistance and, hypertriglycerida-
emia without body weight gain in diabetic rats [4–7]. In healthy
adult volunteers, maximal inhibition of glucose reabsorption by
dapaglifozin has been achieved at a dose of 20 mg, with a terminal
half life of around 17 h, with a stable plasma level of over 2 weeks
(ideal for once daily administration). Dapaglifozin availability only
changes slightly when taken with foods and mainly excreted in ur-
ine as glucuronide [8].
The potential anti-diabetic effect of SGLT-2 inhibitors is cur-
rently under considerable investigation, and has reached the level
of clinical trials. Komoroski et al. administered dapagliﬂozin to
type 2 diabetic individuals for 14 days in a randomized study to
four treatment groups receiving daily oral doses of 5-, 25-, or
100-mg doses of dapagliﬂozin or placebo. Signiﬁcant reductions
in fasting serum glucose were observed on day 2 with 100 mg
dapagliﬂozin (9.3%, P < 0.001), and dose-dependent reductions
were observed on day 13 with the 5-mg (11.7%; P < 0.05),pen access under CC BY-NC-ND license.
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as compared with the placebo. Signiﬁcant improvements in oral
glucose tolerance test were observed with all doses on days 2
and 13 (P < 0.001 as compared with the placebo). On day 14, urine
glucose values were 36.6, 70.1, and 69.9 g/day for the 5-, 25-, and
100-mg doses (as compared with no change for placebo), which
were slightly lower than those on day 1. This was attributed to
the decrease in ﬁltered glucose load following improved glycemic
control [9]. Interestingly the administration of dapaglifozin on a
chronic basis is also associated with a favourable metabolic out-
come. List et al. showed that administration of dapaglifozin for
12 weeks in type 2 diabetic individuals was associated with in-
duced moderate glucosuria (52–85 g urinary glucose/day) and sig-
niﬁcant glycemic improvements versus placebo (A1C 0.55 to
0.90% and fasting plasma glucose 16 to 31 mg/dl). Weight loss
change versus placebo was 1.3 to 2.0 kg. The authors concluded
that dapagliﬂozin improved hyperglycaemia, and facilitates weight
loss in type 2 diabetic patients by inducing controlled glucosuria,
with a urinary loss of approximately 200–300 kcal/day without
alteration in renal function [10]. Importantly, Wilding et al.
showed that SGLT-2 inhibition can improve glycaemic control
and weight in individuals with diabetes that is poorly controlled
with high insulin doses and oral insulin sensitizer therapy, despite
a 50% insulin dose reduction [11].
In summary, the administration of SLGT-2 inhibitors appears to
induce glucosuria and signiﬁcantly improves glycaemic control in
patients with type 2 diabetes without risk of severe hypoglycae-
mia. Hypertension is known to be very common among diabetic
individuals and may be diagnosed many years before diabetes. It
was postulated that SGLT-2 inhibitors may have a diuretic-like ac-
tion. In addition to treating hypertension SGLT-2 inhibitors may be
favourable option with administration of glitazones which are
known to cause ﬂuid retention. Weight reduction achieved with
an administration of SGLT-2 for 12 weeks may raise hopes in hori-
zon but not before establishing whether administration of such
agents may increase the risk of genital fungal infections. One po-
tential beneﬁt we all hope to gain from SGLT-2 inhibitors in addi-
tion to improving glycaemic control is whether they will protect
against diabetic nephropathy. Currently, we probably all agree that
it is too early to discuss how SGLT-2 inhibitors may modulate car-
diovascular disease. Importantly, the intensive glycaemia control
intervention used in the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trial was associated with increased mortality
and increased rates of severe hypoglycaemia. The ACCORD trial
demonstrated that patients with type 2 diabetes who experience
symptomatic, severe hypoglycaemia are at increased risk of death,
regardless of the intensity of glucose control [12]. The main con-
cern with fasting Ramadan and the use of insulin and antidiabetic
medication is an association with high risk of hypoglycaemia [13].
The population based Epidemiology of Diabetes and Ramadan
1422/2001 (EPIDIAR) study conducted in 13 Islamic countries
showed that 43% of type1 diabetes and 79% of type 2 fast during
Ramadan [14]. In view of the absence of risk of hypoglycaemia
with SGLT-2 inhibitors, it is very tempting to postulate that these
agents may provide a promising new approach in treating diabe-
tes during the fasting month of Ramadan. Importantly, administra-
tion of dapagliﬂozin for 12 weeks has shown improvement inhyperglycaemia without clinically persistent electrolytes distur-
bances or change in osmolarity [10].
3. Conclusion
In summary administration of SLGT-2 inhibitors appears to in-
duce glucosuria and signiﬁcantly improves glycaemic control in
patients with type 2 diabetes without signiﬁcant risk of severe
hypoglycaemia, changes in renal function or plasma electrolytes
disturbances. Taken together, this may suggest that SGLT-2 inhib-
itors may emerge as potential anti-diabetic agents during Rama-
dan. It is not yet established whether administration of such
agents may increase the risk of genital fungal infections. Therefore,
it is possible to suggest that a clinical trial designed to investigate
the potential of SGLT-2 inhibitors for optimizing glycaemic control
in diabetic population during Ramadan is now warranted. Perhaps
this could be an important gain from this new anti-diabetic
medication.
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